A ngiotensin II (ANG), the main active peptide of the renin-angiotensin system, acts at 2 distinct receptor subtypes, namely type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The role of AT 1 receptors in the regulation of cardiovascular functions, fluid homeostasis, and hormone release is well established, and several AT 1 receptor antagonists are used for the treatment of hypertension. 1 In rodents, 2 pharmacologically similar AT 1 receptor isoforms, AT 1A and AT 1B , exist, which are encoded by 2 distinct genes and are expressed and regulated differentially. [2] [3] [4] [5] High levels of AT 1A receptor mRNA are present in the rodent brain, kidney, and vasculature, whereas AT 1B receptor mRNA is mainly expressed in the pituitary and adrenal glands. 6 -10 Although widely expressed in fetal and young rats, 11 in adult rats, the expression of AT 2 receptors is low and restricted to certain organs, such as the brain and adrenal gland. 1, 12 The expression of all ANG receptor subtypes in the hypothalamo-pituitary-adrenal (HPA) axis, which is activated in response to stress, as well as the regulation of ANG receptors by restraint stress [13] [14] [15] implies important roles of the ANG system in the regulation of the activity of the HPA axis. Accordingly, ANG has been shown to regulate corticotropin-releasing factor, adrenocorticotropic hormone (ACTH), and corticosterone synthesis and secretion. 16 -18 Spontaneously hypertensive rats (SHR) show an impaired response and habituation to various forms of stress such as immobilization and exposure to heat or open field, and they differ in their neuroendocrine reaction to stress from normotensive Wistar-Kyoto rats (WKY). 19 -23 The ANG system has been implicated in the impaired stress response of SHR. 24 -27 There are several studies showing differences in the numbers of binding sites for radiolabeled ANG between SHR and WKY in the kidney, vasculature, heart, pituitary, adrenal gland, and brain, including the hypothalamus and neuronal cultures. 28 -32 Because AT 1A and AT 1B receptors are pharmacologically indistinguishable, the distinct expression of these AT 1 receptor isoforms was not addressed in these studies. Using a different approach, Iwai et al 33 could not detect differences of AT 1A mRNA levels in the brain and adrenal gland between WKY and SHR, whereas Raizada et al 34 found increased AT 1A and AT 1B receptor mRNA levels in the hypothalamus of SHR compared with WKY. Furthermore, AT 1B receptor mRNA appeared to be upregulated in the heart ventricle of SHR. 2 Nevertheless, thus far, no information is available regarding the gene expression of AT 1A and AT 1B receptor subtypes in the pituitary and of AT 1B receptors in the adrenal gland of SHR in comparison to WKY. Therefore, we analyzed the mRNA expression of AT 1A , AT 1B , and AT 2 receptor subtypes in the hypothalamus, pituitary, and adrenal gland of SHR at different developmental stages of hypertension in comparison with age-matched normotensive WKY.
Methods

Animals and Treatments
Male SHR and age-matched WKY at 3 different postnatal ages corresponding to the prehypertensive (3 to 4 weeks), developing (7 to 8 weeks), and established (12 to 13 weeks) stages of hypertension were purchased from Charles-River. Rats were kept under controlled conditions with a 12 hour/12 hour dark/light cycle and ad libitum access to standard diet and water. For RNA analysis, rats were anesthetized with pentobarbital (50 mg/kg IP) and killed by decapitation. Tissues were removed immediately, frozen in isopentane (Ϫ30°C), and stored at Ϫ80°C until use.
To measure the effect of ANG on adrenal hormones, 12-week-old male SHR and WKY were treated with a single intraperitoneal injection of dexamethasone (100 g) to suppress ANG-induced ACTH release. 35 Three hours after injection, rats were anesthetized with 100 mg/kg IP methohexital, and the right femoral artery was catheterized. Anesthesia was continued with 5 mg IA pentobarbital; 1 or 10 g ANG was infused over a period of 30 minutes, and 500 L blood was withdrawn for hormone assays. All animal protocols complied with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Ministerium für Umwelt, Natur und Forsten of Schleswig-Holstein, Germany (animal protocol 9/A37/01).
RNA Isolation and cDNA Synthesis
Hypothalami were dissected according to Palkovits and Brownstein. 36 The brains were adapted to Ϫ10°C, and coronal cuts were made at 900 m (at the optic chiasm) and 4800 m (just posterior of the mamillary nucleus) posterior of the bregma. The hypothalamic slice was turned on its posterior surface and cut laterally directly before the amygdala and dorsally just underneath the anterior commissure.
Hypothalami and pituitary and adrenal glands were homogenized in the presence of guanidinium isothiocyanate. Total RNA was isolated with the use of silica gel-based spin columns and treated with DNase I (RNeasy Kit, Qiagen GmbH). First-strand cDNA was synthesized from 1 g total RNA in a volume of 20 L containing 5 mmol/L MgCl 2 , 10 mmol/L Tris-HCl, pH 9.0, 50 mmol/L KCl, 0.1% Triton X-100, 1 mmol/L dNTPs, 1 U/L RNasin, 0.5 g oligo-(dT) 15 primer, and 15 U AMV reverse transcriptase (Promega GmbH). By performing PCR in control samples in which the reverse transcriptase was omitted, possible contamination with genomic DNA was monitored. As a control for RNA integrity and successful cDNA synthesis, the ␤-actin mRNA expression of each sample was analyzed by RT-PCR.
Semiquantitative PCR
AT 1 receptor primers spanning identical regions of the AT 1A and AT 1B receptor cDNA were used. 3, 37 According to Ruan et al, 38 the amplified AT 1A and AT 1B receptor cDNA was identified by restriction with EcoR I ( Figure 1A ). AT 2 receptor and ␤-actin specific sense and antisense primers were designed on the basis of the published cDNA sequences. 39, 40 All primers (Table) were constructed with the use of Primer3 software by S. Rozen and H.J. Skaletsky (http:// www-genome.wi.mit.edu/genome_software/other/primer3.html) and were obtained from Live Technologies GmbH (Karlsruhe, Germany). PCR was performed as described previously. 41 Five microliters of first-strand cDNA was incubated in the presence of 10 mmol/L Tris-HCl, pH 9.0, 50 mmol/L KCl, 0.1% Triton X-100, 1.5 mmol/L MgCl 2 , 0.2 mmol/L dNTPs, 0.5 nmol/L sense and antisense primers, and 1.2 U DNA Polymerase (DyNAzyme II, Biometra GmbH) in a final volume of 50 L. The PCR conditions were 28 to 32 cycles of denaturation for 1 minute at 95°C, annealing for 30 seconds at 56°C, and extension for 60 seconds at 72°C. The specificity of the amplified AT 1A and AT 1B receptors cDNA was confirmed by restriction with Alu I, which cuts the AT 1A receptor cDNA to 20, 54, 83, and 154 bp fragments and the AT 1B receptor cDNA to 103-bp and 208-bp fragments ( Figure 1A ). EcoR I selectively cuts the AT 1A receptor cDNA to 128-and 183-bp fragments and leaves the AT 1B receptor cDNA intact ( Figure 1A ). AT 2 receptor cDNA was restricted with Ssp I to 26-, 92-, and 131-bp fragments.
For semiquantitative analysis of AT 1 and AT 2 receptor mRNA levels, agarose gels were digitized and analyzed densitometrically with Scion Image for Windows (Scion Co), which is based on the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http:// rsb.info.nih.gov/nih-image). To ensure amplification within the exponential phase of the PCR, the PCR cycle numbers used for AT 1A , AT 1B , and AT 2 receptor and ␤-actin cDNA amplification were optimized for each primer pair and tissue by kinetic analysis (22 to 40 cycles). Depending on the primers and tissues, cycle numbers between 28 and 32 were found to produce exponential amplification of PCR products. The mRNA levels of ␤-actin were used as internal standard to normalize AT 1 and AT 2 receptor mRNA levels. 41 
Nucleotide Sequences of PCR Primer
cDNA Cloning and In Vitro Transcription of Riboprobes
Adrenal cDNA was amplified by PCR with the following AT 1B receptor specific primers, which amplify a part of the 3Ј-noncoding region without significant homology to the AT 1A receptor cDNA: sense primer 5Ј-GTGGAGTGAGAGGGTTCAA-3Ј and antisense primer 5Ј-GACATTATTCAGGCAAGCTG-3Ј, spanning nucleotides 1268 to 1896 of the published AT 1B receptor cDNA. 3 The amplified AT 1B receptor cDNA was subcloned into the pCR-II Vector with the use of a TA-cloning kit (Invitrogen), and its identity was confirmed by nucleotide sequencing (MWG Biotech 
In Situ Hybridization Histochemistry
In situ hybridization was performed as described earlier. 42 Adrenal glands from SHR and WKY were sectioned at Ϫ20°C in a cryostat, and 20-m sections were thaw-mounted alongside on aminoalkylsilane-coated glass slides (Sigma). After fixation in 4% paraformaldehyde for 10 minutes, sections were dehydrated in ethanol and air-dried. Hybridization was performed with 1 to 2 pmol/mL labeled RNA-probes in buffer containing 50% formamide, 10% dextran sulfate, 1ϫDenhardt's solution, 20 mmol/L Tris (pH 7.5), 0.3 mol/L NaCl, 1 mmol/L EDTA, 150 mmol/L dithiothreitol, 0.2% sodium dodecyl sulfate, 100 g/mL salmon sperm DNA, and 250 g/mL yeast tRNA for 18 hours at 54°C. Subsequently, sections were treated with RNAse A, washed in NaCl-Na citrate (SSC) buffer to a final stringency of 0.1ϫSSC at 60°C, dehydrated in ethanol, and exposed to Hyperfilm H 3 (Amersham-Pharmacia) along with C-14 standards (American Radiolabeled Chemicals, Inc). Films were analyzed densitometrically with Scion Image. 42 
Radioimmunassays
Plasma concentrations of ACTH, corticosterone, and aldosterone were measured with the use of 125 I radioimmunoassay kits (ICN Biomedicals). For aldosterone detection, 100 L serum was extracted twice with 2 mL ethyl acetate/hexane (3:2), evaporated, and reconstituted in 1 mL RIA buffer; 250 L was used in the assay. For corticosterone detection, 100 L serum was diluted 1:200 with RIA buffer and 100 L thereof was used in the assay. For ACTH detection, 100 L serum was used without dilution. All samples were assayed in duplicate according to the manufacturers instructions. Intra-assay and interassay variations were Ͻ6% and 10%, respectively.
Statistics
Data are presented as meanϮSEM. Effects of age and genetic groups were estimated by 2-way ANOVA, with the use of GraphPad Prism Software (GraphPad Software Inc). Effects of ANG on plasma hormones were analyzed by 1-way ANOVA. For subsequent group comparisons the Bonferroni posttest was used. Probability values Ͻ0.05 were considered statistically significant.
Results
Specific Amplification of ANG Receptor Subtypes
RT-PCR with AT 1 receptor-specific and AT 2 receptor-specific sense and antisense primers resulted in the amplification of distinct cDNA fragments of the expected size of 311 bp and 249 bp, respectively (Figure 1 ). Restriction analysis of the amplified AT 1 and AT 2 receptor cDNA confirmed the specificity of our PCR showing the restriction fragments as predicted according to the published cDNA sequences (Figure 1) . Restriction with EcoR I, which selectively cuts AT 1A but not AT 1B receptor cDNA, allowed the differentiation between these 2 AT 1 receptor isoforms (Figure 2) . In samples in which the RT was omitted and in water control reactions, no amplification products were observed after PCR. The integrity of the cDNA was confirmed by analysis of ␤-actin mRNA.
Distribution of ANG Receptor Subtypes in the HPA Axis
In normotensive WKY, AT 1A receptor mRNA was mainly expressed in the hypothalamus and adrenal glands and was very low in the pituitary gland, whereas AT 1B receptor mRNA was primarily found in the pituitary and adrenal glands (Figure 2) . AT 2 receptor mRNA was highly expressed in the adrenal glands and at lower levels in the hypothalamus (Figure 3 ). No AT 2 receptor mRNA was detected in the pituitary gland.
Expression of ANG Receptor Subtypes in WKY and SHR
In the hypothalamus, no differences were detected in AT 1A , AT 1B , or AT 2 receptor mRNA levels between SHR and WKY at different postnatal ages corresponding to the prehyperten- sive (3 to 4 weeks old), developing (7 to 8 weeks old), and established (12 to 13 weeks old) stages of hypertension, although there was a tendency of lower AT 1A and AT 1B receptor mRNA in prehypertensive SHR (Figure 4 ). In the pituitary gland, we detected significantly higher levels of AT 1A receptor mRNA and significantly lower levels of AT 1B receptor mRNA at all postnatal ages ( Figure 5 ). In the adrenal gland, AT 1B receptor mRNA levels were significantly reduced in 7-to 8-and 12-to 13-week-old SHR when compared with WKY ( Figure 6 ). Adrenal AT 2 receptor mRNA levels were high in 3-to 4-week-old rats and declined to some extent with age ( Figure 6 ). No significant differences were found in adrenal AT 1A or AT 2 receptor mRNA levels between SHR and WKY at the different ages ( Figure 6 ). On the whole, there was a tendency of reduced AT 2 receptor mRNA levels in the adrenal of SHR.
Localization of AT 1B Receptor mRNA in the Adrenal Gland of WKY and SHR
The AT 1B receptor mRNA expression in the adrenal gland of WKY and SHR was localized exclusively in the zona glomerulosa by in situ hybridization with specific AT 1B receptor antisense RNA probes (Figure 7) . Hybridization with control sense RNA probes resulted in a very low background signal (not shown). Semiquantitative analysis demonstrated reduced AT 1B receptor mRNA levels in the zona glomerulosa of 12-to 13-week-old but not in 7-to 8-week-old SHR when compared with WKY ( Figure 7) .
Effect of ANG on Plasma Hormones in Dexamethasone-Treated WKY and SHR
Infusion of a low dose of ANG (1 g) over a period of 30 minutes had no effect on plasma levels of ACTH, corticosterone, and aldosterone in dexamethasone-treated WKY or SHR (Figure 8 ). However, a high dose of ANG (10 g) significantly increased plasma levels of ACTH and corticosterone in dexamethasone-treated SHR but not in dexamethasone-treated WKY ( Figures 8A and 8B ). Plasma levels of aldosterone were equally increased in both WKY and SHR after infusion of 10 g ANG ( Figure 8C ).
Discussion
The current results demonstrate for the first time the differential mRNA expression of AT 1A and AT 1B receptors in the pituitary and adrenal glands of SHR compared with WKY. The changes in pituitary and adrenal mRNA levels of AT 1A and AT 1B receptors in SHR are accompanied by an increased responsiveness of the HPA axis to ANG in dexamethasonesuppressed animals.
ANG regulates blood pressure by regulating the vascular tone and fluid homeostasis, which are controlled by the stimulation of aldosterone, norepinephrine, and vasopressin release, effects mediated by AT 1 receptors. 1, 43, 44 Little is known about the relative physiological roles of the 2 AT 1 receptor isoforms that are found in rodents. Recent results in AT 1A and AT 1B receptor-deficient mice have shown the involvement of central AT 1A receptors in the regulation of blood pressure and fluid homeostasis and that of central AT 1B receptors in drinking behavior. 45, 46 Because AT 1A and AT 1B receptors cannot be distinguished pharmacologically or by immunohistochemistry, we assessed the mRNA expression of these AT 1 receptor isoforms by semiquantitative RT-PCR combined with receptor isoform-specific restriction of the PCR products. 38 Using this method, we confirmed the tissuespecific distribution of AT 1A , AT 1B , and AT 2 receptor mRNA and their high expression in the HPA axis. 6 -10 In the pituitary gland of SHR, we found AT 1A receptor mRNA levels notably increased compared with WKY, whereas AT 1B receptor mRNA levels were decreased, and these differences were evident at a young age, before the onset of hypertension. Reduced ANG binding sites in the anterior pituitary of SHR as described earlier 47 may reflect this decrease in AT 1B receptor expression. However, since in normotensive adult rats pituitary AT 1A receptor mRNA levels are usually very low or undetectable, 8 ,10,48 the significant 
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mRNA expression of pituitary AT 1A receptors in adult SHR in the current study also suggests specific ANG-related functional changes of the pituitary gland in SHR. Although AT 1B receptors appear to be mainly expressed in prolactinproducing pituitary cells and to a lower degree in ACTHproducing cells, 48 the pituitary cells expressing AT 1A receptors were not identified thus far, and considerations about possible functions of pituitary AT 1A receptors in SHR are only speculative at this point. ANG was shown to directly affect pituitary prolactin, ACTH, and growth hormone release, 49 -51 and these effects appear to be mediated differentially by AT 1A and AT 1B receptors. For example, ANG may directly stimulate prolactin release from the pituitary gland by acting on AT 1B receptors and inhibit pituitary prolactin indirectly by stimulating dopamine release through central AT 1A receptors. 42 Earlier studies on the pituitary hormonal system revealed higher basal prolactin in SHR 19 and enhanced growth hormone but not prolactin secretion from pituitary cells after ANG in SHR. 52 Thus, reduced pituitary mRNA levels of AT 1B receptors in SHR may reflect adaptive changes to high prolactin levels caused by other secretagogues. We found elevated plasma levels of ACTH and corticosterone in response to ANG in dexamethasone-treated SHR but not in dexamethasone-treated WKY. Since this increased responsiveness to ANG is associated with an increased mRNA expression of AT 1A receptors and a decreased mRNA expression of AT 1B receptors in the pituitary, the pituitary AT 1A receptor may account for the ANG-induced elevation of plasma ACTH and a consequent increase of plasma corticosterone in SHR. Interestingly, restraint stress results in a similar shift of pituitary AT 1A and AT 1B receptor expression. 15 Thus, the increased pituitary AT 1A receptors may make SHR more susceptible to stress. However, the detailed physiological role of the pituitary AT 1A receptors in SHR remains unclear and awaits further clarification.
One of the main AT 1 receptor-mediated effects of ANG is the stimulation of aldosterone release from the adrenal gland. 43 The finding that the aldosterone response to sodium depletion is not influenced in AT 1A receptor-deficient mice suggests a major role of the AT 1B receptor. 53 Indeed, although AT 1A receptors are present in all cortical layers and the medulla of the adrenal gland, 9 we found AT 1B receptor mRNA highly and specifically expressed in the zona glomerulosa, in accordance with earlier studies. 8, 9 Furthermore, we show that the reduced adrenal AT 1B receptor mRNA levels in SHR are localized exclusively in the aldosteroneproducing zona glomerulosa. Thus, our data suggested an impaired aldosterone response to ANG in SHR. However, in dexamethasone-treated WKY and SHR, we found a similar increase of plasma aldosterone after ANG treatment. Since plasma aldosterone levels appear to be increased in SHR, 19 reduced AT 1B receptor mRNA levels may reflect adaptive changes to reduce aldosterone release and to protect from excess aldosterone. On the other hand, changes in AT 1B receptor mRNA levels may not translate to changes in protein levels. The dose of dexamethasone we used was shown to efficiently suppress ANG-dependent ACTH release in normotensive Sprague-Dawley rats. 35 In contrast to dexamethasone-treated WKY, ANG still increased ACTH in dexamethasone-treated SHR. Thus in SHR, ANG-induced ACTH release may also contribute to the aldosterone release. We found no differences in the mRNA levels of adrenal AT 2 receptors between WKY and SHR. The decrease of adrenal AT 2 receptor mRNA levels with increasing age is in line with earlier observations in adrenals and many other tissues. 1 Figure 7 . Localization of AT 1B receptor mRNA in adrenal gland of 3-to 4-week-old and 12-to 13-week-old SHR and age-matched WKY by in situ hybridization (A) and semiquantitative analysis of AT 1B receptor mRNA levels in the adrenal zona glomerulosa (B). Values are meanϮSEM (nϭ6 per group). ***PϽ0.001. In the hypothalamus, we did not find differences in AT 1 receptor mRNA levels between SHR and WKY despite previous findings of an increase of AT 1 receptor mRNA in the hypothalamus and brain stem of SHR compared with WKY. 34 However, our findings correspond to previous results showing that ANG binding sites were unaffected in various hypothalamic and brain stem nuclei of SHR, except for the spinal trigeminal nucleus, when compared with WKY. 30 Hence, differences in AT 1 receptor mRNA might be restricted to distinct brain nuclei and therefore not accessible by our method. Nevertheless, we found significant differences in the mRNA expression of AT 1A and AT 1B receptors in the pituitary and adrenal gland of SHR compared with WKY. These differences occurred before the onset of hypertension and in the phase of developing high blood pressure. Thus, a causal role between an exaggerated stress response and an altered expression of pituitary and adrenal AT 1 receptors may exist. This correlation is further supported by our findings in SHR of an enhanced activity of the HPA axis in response to ANG. Interestingly, the regulation of pituitary and adrenal AT 1A and AT 1B receptor mRNA in SHR, as described in our current study, shows similarities with the increased pituitary AT 1A receptor and decreased pituitary and adrenal AT 1B receptor expression found in rats after immobilization stress. 15 Our data suggest that the known susceptibility of SHR to stress is linked to the differential expression of pituitary and adrenal AT 1A and AT 1B receptors and support an important role of the ANG system in the regulation of the stress response in SHR.
Perspectives
In humans, enhanced stress reactivity may be involved in combination with other environmental and genetic factors in the development of hypertension. 54 In contrast to rodents, a single gene encodes the human AT 1 receptor. 55 However, several splicing variants of the human AT 1 receptor exist that are not only expressed differentially but are functionally different. 56, 57 Since the physiological response of AT 1 receptors to ANG is very similar in humans and rodents, a better understanding of divergent regulations and functions of AT 1 receptor isoforms in rodents may help to elucidate the involvement of AT 1 receptor isoforms in the development of stress-related disorders in humans, including hypertension. 
